We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Liquid Nitrogen Cryoablation System Treats Kidney Tumors

By HospiMedica International staff writers
Posted on 02 Apr 2019
A minimally invasive cryoablation system uses next generation liquid nitrogen (LN2) technology to enable the treatment of benign and cancerous tumors by freezing, without surgery.

The IceCure Medical (Caesarea, Israel) ProSense cryoablation system uses extreme cold to freeze tumors using a cryoprobe that delivers LN2 gas--which has a sub-zero boiling point--to the tip, which absorbs tissue-generated heat until the tissue freezes, forming an “ice-ball.” A computer-controlled regulator modulates the flow of LN2 gas, generating a “freeze-thaw-freeze” cycle that weakens cell wall membranes. More...
As a result, they rupture, and intracellular antigens can trigger cell-specific immune responses and platelets can block adjacent capillaries, cutting off the tumor’s blood supply.

By replacing traditional argon gas, with a boiling point of -185.8° C, with liquid nitrogen, which boils at 196° C, the cryoablative effect is enhanced. This also eliminates the need for large storage tanks that are required for argon, as LN2 remains stable at room temperature under very low pressure. A very thin 3.4 mm cryoprobe is used to prevent scar formation and, coupled with the analgesic effect of extreme cold, pain and the need for anesthesia are prevented. The necrotic debris is eventually reabsorbed by the body, leaving no artifacts to complicate diagnostic accuracy.

In a recent study presented at the 34th annual European Association of Urology Congress, held during March 2019 in Barcelona (Spain), the ProSense system proved safe, effective, and devoid of serious adverse events in the treatment of small kidney tumors. Of 74 patients with 78 small kidney masses (less than four 4 cm in diameter), the ProSense system showed treatment success by lack of enhancement on computerized tomography (CT) or magnetic resonance imaging (MRI) in 93% of cases at one year follow-up.

“The ProSense system enables a safe, efficient, and short minimal-invasive procedure that preserves renal function,” said senior author Professor Ofer Nativ, MD, head of the Bnei Zion Hospital (Haifa, Israel) urology department. “There were over 400,000 new cases worldwide in 2018. The ProSense system adds a viable option to treat renal cancer in patients who have at least one comorbidity, had surgeries in the past, or are a subject to multiple renal masses.”

Related Links:
IceCure Medical
Bnei Zion Hospital


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.